Profil d'innocuité du Baricitinib chez les patients atteints de polyarthrite rhumatoïde active, traités plus de 2 ans en moyenne
J Rheumatol. 2019 Jan;46(1):7-18. DOI: 10.3899/jrheum.171361
Baricitinib (BARI) showed an acceptable 5.5-year safety profile in this integrated analysis of patients with moderate-to-severe, active RA.This study evaluated the safety profile of the oral, once daily Janus kinase inhibitor, BARI, in adults with moderately to severely active RA. Data from eight randomised clinical trials and one long-term extension study were pooled and analysed for placebo comparison and dose response.There were 3492 patients who received BARI for a total of 6637 patient-yea...